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Abstract
Background: In this study we sought to determine if application of bone morphogenic protein 7 (BMP-7)
promotes physiological bone healing of non-unions and to investigate if serum cytokine analysis may serve as
a promising tool in the analysis of adjunct non-union therapy. Therefore we analyzed the influence of BMP-7
application on the serum cytokine expression patterns on patients with impaired bone healing compared to
patients that showed proper bone healing.
Methods: Our study involved analyzing blood samples from 208 patients with long bone fractures together with
patients that subsequently developed non-unions. From this large pool, 15 patients with atrophic non-union were
matched to 15 patients with atrophic non-union treated with local application of BMP-7 as well as normal bone
healing. Changes in the cytokine expression patterns were monitored during the 1st, 2nd, 4th, 8th, 12th and 52nd
week. The patients were followed both clinically and radiologically for the entire duration of the study. Serum
cytokine expression levels of transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF) and
basic fibroblast growth factor (bFGF) were analyzed and compared.
Results: Serum expression of TGF-β were nearly parallel in all three groups, however serum concentrations were
significantly higher in patients with proper bone healing and those treated with BMP-7 than in patients with non-unions
(p < 0.05). bFGF serum concentrations increased initially in patients with proper bone healing and in those treated with
BMP-7. Afterwards, values decreased; bFGF serum concentrations in the BMP-7 group were significantly higher than in the
other groups (p< 0.05). PDGF serum concentration levels were nearly parallel in all groups, serum concentrations were
significantly higher in patients with proper bone healing and those treated with BMP-7 than in patients with non-unions
(p < 0.05).
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Conclusion: Treatment with BMP-7 in patients with former non-unions led to similar cytokine expression patterns
after treatment as those found in patients with proper bone healing. Our results suggest that treatment with BMP-7
promote healing of non-unions. Furthermore, quantitative measurement of serum cytokine expression is a promising tool
for evaluating the effectiveness of additional non-union therapies such as adjunct application of growth factors.
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Background
The therapy of non-unions in trauma surgery still re-
mains a challenge [1]. Currently there are various surgi-
cal treatment options for non-unions [2], including
revision surgery, medullary reaming, and dynamisation
of nails. The gold standard for treating non-unions is the
use of autologous bone grafts [3] harvested from the
iliac crest, which have osteogenic, osteoinductive, and
osteoconductive properties [4, 5]. Patients who do not
respond to such therapies require further surgical inter-
ventions, such as adjunct application of bone morpho-
genic protein 7 (BMP-7) during revision surgery.
In the last 20 years, various attempts have been made
to develop treatment plans involving growth factors for
non-unions. BMP-7, a member of the transforming
growth factor beta (TGF-β) - superfamily, is one of the
first growth factors that was approved for clinical use.
Originally applied for non-unions of the tibia, it has
been used on many localizations for over 10 years with-
out significant complications [6]. In clinical studies,
BMP-7 was documented as being 80–90 % effective in
healing non-unions, showing comparable or even better
results as autologous bone grafting [7, 8].
Despite its potential for therapy, the success of
BMP-7 on fracture healing has only been confirmed
through radiological and clinical parameters in
humans. A major disadvantage of these methods is
that evaluation of fracture healing is only possible
after at least 3 months [9], and the frequency of x-ray
and CT imaging is limited due to radiation exposure.
Studies on the modulating effects of BMP-7 on serum
cytokine levels in animals are limited in their transfer-
ability to humans [10].
In this clinical study, we analyzed the effects of
BMP-7 application during non-union therapy on hu-
man serum cytokine levels during a 1 year follow-up
study. The basis for our research concept came from
previous studies, in which we described several cyto-
kine expression patterns in regular and failed bone
healing [11–14]. We were able to detect significant
differences in expression patterns at certain time
points, which suggested that fracture healing was
delayed or failed. In a further study we could show
that smoking decreased the expression of TGF-β in
patients after surgery [15]. From these studies we
concluded that measuring serum cytokine expression
is a valid instrument for evaluating bone healing [15,
16]. We chose to use this concept in order to investi-
gate if treatment with BMP-7 may promote physio-
logical healing of non-unions and if quantitative
measurement of serum cytokine expression is a prom-
ising tool in the future for evaluating the effectiveness
of additional non-union therapies such as adjunct
application of growth factors.
Methods
Patient recruitment, clinical investigation
Two hundred and eight Patients (159 men, 49 women,
aged 18 to 76 years) were enrolled in our study at BG
Trauma center Ludwigshafen between 2002 and 2007.
Inclusion criteria were diaphyseal fractures of long bones
(humerus, radius, ulna, femur, tibia). Exclusion criteria
were the existence of systemic diseases such as hypo- or
hyperthyroidism, diabetes mellitus, advanced liver dis-
ease, chronic inflammatory diseases, malignancy, and
extreme obesity as well as long-term use of immunosup-
pressive drugs, which can influence normal cytokine
levels. All enrolled patients were invited to attend
follow-up examinations at standardized intervals: 1, 2,
4, 8, 12 weeks and 1 year after surgery. Blood samples
were taken at every follow-up examination. Patients
with radiological and clinical evidence of failed fracture
healing and formation of a non-union underwent revi-
sion surgery involving debridement, BMP-7 application,
and re-osteosynthesis. In these cases, blood samples
were taken until definitive healing of the fracture could
be confirmed.
Of the 208 patients, 160 showed proper bone heal-
ing according to x-ray results, clinical stability, and
pain-free weight-bearing; 48 patients suffered from
non-unions, from which 13 patients received treat-
ment with BMP-7. Furthermore, 18 patients were
treated with BMP-7 in our hospital after failed pri-
mary treatment elsewhere. We included these patients
in the follow-up schedule mentioned above. The study
was conducted in accordance with the declaration of
Helsinki and after the approval of the ethics commit-
tee of the Ruprechts-Karls-University of Heidelberg
(nr. 157/2002).
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Matching
We compared three groups of patients:
1. Fracture patients developing non-unions
2. Non-union patients treated with BMP-7
3. Fracture patients with proper healing
Patients with fractures that failed to heal after primary
treatment were assigned to the non-union group. After
treatment with BMP-7, these Patients were assigned to
the BMP-7 group. In two cases, this was not possible, so
we matched two patients with two BMP-7 patients. We
matched the two groups with a third group of patients
with proper fracture healing. Patients were matched on
the basis of five criteria: age (+/−5 years), sex,
localization of fracture, type of fracture (classification by
the “Association for the Study of Internal Fixation” (AO/
ASIF)) and type of osteosynthesis. If more than one
match was found for a non-union patient, than the
patient with the most similar type of fracture was
chosen. According to matching criteria three groups (n
= 15) could be formed of the above mentioned total
study patients, whereby patients that developed a non-
union and subsequently were treated with BMP-7 were
assigned to two groups (Table 1).
Administration of BMP-7
Patients that showed radiological and clinical evidence
of failed fracture healing and formation of a non-union
during the follow-up examinations subsequently under-
went revision surgery. In particular revision surgery in-
cluded radical debridement and resection of avital bone
tissue and furthermore re-osteosynthesis was performed,
providing a better biomechanical stability. Hereafter the
defect site was filled with autologous bone marrow that
has an osteogenic potential, thus able of forming bone
independently [17]. To maximize the effect the autolo-
gous bone marrow was enhanced by a nonrecurring
local application of 3.3 mg BMP-7 [18–21].
Sample acquisition and measuring of serum cytokines
Venous blood samples from all patients were collected
during follow-ups. Samples were drawn between 8 a.m.
and 11 a.m. on an empty stomach. Serum was separated,
and stored at−80 °C. Serum samples were thawed and
equilibrated to room temperature for at least 2 h before
analysis. Measurement was set in duplicates. Serum
levels of TGF-β-1, PDGF and bFGF were measured with
commercially available ELISA kits (‘Quantikine®ELISA
Kits’; R&D Systems, Minneapolis, MN, USA). Assays
were conducted according to the manufacturer’s instruc-
tions. Levels measured 1 year after trauma defined base-
line levels in the union group, whereas levels measured
1 year after failed bone healing respectively revision
surgery were defined baseline in the non-union group
respectively BMP-7 group.
Statistics
Pretrial power analysis revealed a minimum size of nine
patients in each group. Serum levels are expressed as
mean absolute concentrations ± standard error of the
mean (SEM) per time point and group. The 1 year
follow-up serum levels were determined as base levels in
order to facilitate analysis of our data. The Friedman-
test was applied to detect significant changes over time
during the entire investigative period. If significant, the
Wilcoxon signed rank test for paired samples was used
to recognize significant changes between the reference
values and post-traumatic results within both groups.
For statistical comparison of serum values at a certain
time point between groups, the Wilcoxon signed rank
test for paired samples was used. The confidence limit
was predetermined at a level of 0.05. Statistical analysis
was carried out by use of SPSS for Windows 11.0
(Norusis SPSS GmbH Inc.).
Results
TGF-β
Generally speaking, TGF-β serum concentrations in-
creased in all groups during the first 2 weeks after sur-
gery (BMP-7 week 1: 53.80 ± 3.63 ng/ml, week 2:
67.94 ± 2.32 ng/ml; Non-union week 1: 47.90 ±
3.29 ng/ml. week 2: 58.63 ± 2.94 ng/ml; Union week 1:
57.32 ± 4.85 ng/ml. week 2: 62.98 ± 4.59 ng/ml), de-
creased after the 2nd week (BMP-7 week 4: 56.98 ±
2.29 ng/ml, Non-union week 4: 43.64 ± 1.90 ng/ml,
Union week 4: 61.75 ± 4.02 ng/ml), and plateaued after
the 6th week (BMP-7 week 6: 54.36 ± 2.13 ng/ml,
Table 1 Patient demographics and clinical characteristics
Gender Age Type of Fracture (AO) Lokalisation of Fracture Fixation
Patients N ♀ ♂ A B C C1° Femur Tibia Forearm Upper arm Nail Plate Ext. Fix.
All patients 45 9 36 47,37 ±11,54 30 12 15 9 12 48 3 3 27 36 3
Union group 15 3 12 47,2 ±12,00 10 4 5 3 4 16 1 1 9 12 1
Non-union group 15 3 12 47,53 ±11,48 10 4 5 3 4 16 1 1 9 12 1
BMP-7 group 15 3 12 47,53 ±11,48 10 4 5 3 4 16 1 1 9 12 1
Abbreviations: BMP-7 Bone morphogenic protein 7; Ext. Fix. Osteosynthesis by external fixation; AO AO-Classification. Age is expressed as mean years ± SD
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Non-union week 6: 45.90 ± 2.79 ng/ml, Union week 6:
50.72 ± 2.58 ng/ml). Serum concentrations were higher
in patients with proper bone healing and those treated
with BMP-7 than in patients with non-unions (Fig. 1).
Patients with non-unions showed a decrease below
base levels (Base level Non-union: 50.64 ± 2.67 ng/ml)
after the second week. Patients who received treat-
ment with BMP-7 and patients with proper bone heal-
ing showed less decrease in serum concentrations
after the second week and concentrations remained
above base levels (Base level BMP-7: 51.39 ± 2.95 ng/
ml and Union: 48.75 ± 2.82 ng/ml). Differences be-
tween the union and non-union group were significant
in the 4th week (p = 0.00) while differences between
the non-union and the BMP-7 group were significant
in the 2nd, 4th, 8th, and 12th week (p = 0.031; p = 0.00;
p = 0.048; p = 0.026).
PDGF
PDGF serum concentration levels were nearly parallel
in all three groups (Fig. 2). Values increased between
the first and the second week (BMP-7 week 1: 23.25 ±
2.45 ng/ml, week 2: 29.23 ± 3.16 ng/ml; Non-union
week 1: 20.75 ± 2.19 ng/ml, week 2: 26.66 ± 2.50 ng/ml;
Union week 1: 24.78 ± 1.50 ng/ml, week 2: 30.38 ±
1.66 ng/ml) and decreased afterwards (BMP-7 week 8:
25.35 ± 1.65 ng/ml, Non-union week 8: 21.82 ±
1.75 ng/ml, Union week 8: 25.07 ± 1.78 ng/ml). Serum
concentrations in non-union patients were lower than
those in the other groups during the whole study,
declining below the base value (Base level Non-union:
24.18 ± 2.51 ng/ml) after the second week without
reaching this value during the following course. In the
union and the BMP-7 group, values increased slightly
after week 8, and differences in PDGF serum concen-
tration between the union and the non-union groups
as well as between the non-union and the BMP-7-
groups were significant after week 12 (BMP-7 week
12: 26.99 ± 2.04 ng/ml, Non-union week 12: 21.70 ±
1.67 ng/ml, Union week 12: 26.73 ± 1.41 ng/ml; p =
0.033 and p = 0.041 respectively).
bFGF
bFGF serum concentrations increased in between the
first and the second week in patients with proper bone
healing and in those treated with BMP-7 (BMP-7 week
1: 7.96 ± 2.03 ng/ml, week 2: 36.77 ± 10.12 ng/ml; Non-
union week 1: 5.94 ± 1.59 ng/ml, week 2: 6.60 ± 1.08 ng/
ml; Union week 1: 5.09 ± 1.03 ng/ml, week 2: 13.12 ±
1.92 ng/ml) (Fig. 3). Afterwards, values decreased (BMP-
7 week 4: 27.48 ± 9.23 ng/ml, Non-union week 4: 6.85 ±
1.18 ng/ml, Union week 4: 6.05 ± 1.19 ng/ml). Over the
whole investigation period, bFGF serum concentrations
in the BMP-7 group were higher than in the other
groups. In non-union patients, values did not change
significantly during the whole course but varied around
Fig. 1 Analysis of serum TGF-β expression level. TGF-β serum level
comparison over time for the entire study patients divided into groups
(Union: Fracture patients with proper healing, Non-Union: Fracture
patients developing non-unions, BMP-7: Non-union patients treated
with BMP-7) expressed as means and SEM. Serum concentration was
measured in nanogram per milliliter (ng/ml). The Wilcoxon signed rank
test assessed significant differences between both groups at each
particular time point (* indicates significant differences between the
Non-Union and BMP-7 Group, whereas † indicates significant
differences between Union and Non-Union Group p < 0.05)
Fig. 2 Analysis of serum PDGF expression level. PDGF serum level
comparison over time for the entire study patients divided into groups
(Union: Fracture patients with proper healing, Non-Union: Fracture
patients developing non-unions, BMP-7: Non-union patients treated
with BMP-7) expressed as means and SEM. Serum concentration was
measured in nanogram per milliliter (ng/ml). The Wilcoxon signed rank
test assessed significant differences between both groups at each
particular time point (* indicates significant differences between
the Non-Union and BMP-7 Group, whereas † indicates significant
differences between Union and Non-Union Group p < 0.05)
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the base level. Differences between the union and the
non-union group were significant in the second week
and at base levels (Base level BMP-7: 15.01 ± 5.53 ng/ml,
Non-union: 7.43 ± 0.77 ng/ml, Union: 5.09 ± 1.12 ng/ml;
p < 0.05). Differences between the BMP-7 and the non-
union group were significant at week 2, 4, 8 and 12
(BMP-7 week 8: 21.86 ± 5.90 ng/ml, week 12: 18.48 ±
4.07 ng/ml; Non-union week 8: 6.32 ± 1.27 ng/ml, week
12: 7.99 ± 1.21 ng/ml; Union week 8: 5.85 ± 1.49 ng/ml,
week 12: 6.01 ± 1.11 ng/ml) (p = 0.003; p = 0.011; p =
0.011; p = 0.014), differences between the BMP-7 and the
union group were significant at week 4, 8, 12 and at base
levels (p = 0.004; p = 0.002; p = 0.001; p = 0.026).
Serum concentrations corresponded with previous re-
sults in other studies [22–24]. Differences in serum con-
centrations of TGF-β, PDGF, and bFGF were significant
between patients with proper bone healing and non-
union patients. Results showed that the application of
BMP-7 lead to expression patterns similar to those in
patients with proper fracture healing. Interestingly, bFGF
increased to a much higher level after week 2 in the
BMP-7 group compared to other groups. Generally
speaking, TGFβ, PDGF and bFGF concentrations peaked
after week 2 and decreased afterwards, and were lower
in patients with non-unions.
Discussion
In this prospective, controlled clinical study, we analyzed
the serum concentrations of TGF-β, PDGF and bFGF
during a 1 year follow-up in non-union patients treated
with BMP-7 and compared them to the cytokine expres-
sion pattern of patients with failed as well as with
physiological bone healing to determine whether the
local application of BMP-7 modulates the microenviron-
ment in the fracture gap and thereby influences second-
ary bone regeneration.
TGF-ß
Recent studies in fracture healing showed that successful
fracture healing is a complex process involving the
growth and differentiation of mesenchymal stem cells,
regulation of cytokines (inflammatory and osteogenic)
and the resorption of extracellular matrix [25]. The
golden standard in non-union therapy is the transplant-
ation of autologous bone graft [26–29], more recently
this therapy was combined with the application of BMP-
7 and studies show a better outcome after non-union
treatment if BMP-7 was applied [18, 30, 31]. The under-
lying mechanism of the clinical success of BMP-7 appli-
cation remains uncertain. In the current study we
sought to determine the influence of local BMP-7 appli-
cation on successful bone healing utilizing quantitative
serum measurement of osteogenic cytokine expression
pattern. Transforming growth factor beta is initially
secreted from thrombocytes in areas of hematoma after
injury, but later from chondrocytes and osteoblasts dur-
ing fracture healing. It stimulates the proliferation of
different cells including osteoblasts, chrondroblasts, and
chondrocytes [22, 23]. Regarding the serum concentra-
tion of TGF-ß our results showed that patients in the
BMP-7 group had lower levels after the first week com-
pared to the group with physiological bone healing
suggesting that osseous biology was still impaired at this
time. However local application of BMP-7 lead to an
increase in TGF-β after the second week that lasted lon-
ger than in every other group. It has been shown that
the concentrations of bone morphogenic proteins were
decreased in patients suffering from non-union, thereby
indicating that a down-regulation in expression of osteo-
genic BMPs might be responsible for failed fracture heal-
ing [32, 33]. In our study patients with failed fracture
healing were treated with adjunct application of BMP-7
serving as a substitution of known lower BMP concen-
trations in patients with failed fracture healing, thereby
modulating the microenviroment in the fracture gap and
increasing local concentration of BMP-7. BMPs and
TGF-ß are both members of TGF-ß protein superfamily
and promote bone formation. The most important effect
of TGF-ß is the stimulation of the synthesis of compo-
nents of the extracellular matrix (e.g. collagen I and III).
Fig. 3 Analysis of serum BFGF expression level. BFGF serum level
comparison over time for the entire study patients divided into groups
(Union: Fracture patients with proper healing, Non-Union: Fracture
patients developing non-unions, BMP-7: Non-union patients treated
with BMP-7) expressed as means and SEM. Serum concentration was
measured in nanogram per milliliter (ng/ml). The Wilcoxon signed rank
test assessed significant differences between both groups at each
particular time point († indicates significant differences between the
Non-Union and Union Group, * indicates significant differences
between the Non-Union and BMP-7 Group, whereas ‡ indicates
significant differences between Union and BMP-7 Group p < 0.05)
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This has been shown to be pivotal in the early stages of
bone healing as scaffolding for later bone mineralization
[34]. BMPs facilitate osteogenic differentiation due to
various pathways in order to achieve successful bone
healing [34]. Peak concentrations in the BMP-7 group
were measured after week 4, suggesting that BMP-7 was
able to stimulate osteoblast biology and lead to higher
expression of TGF-β. BMP-7 appears to have its most
significant impact between week 2 and 4 [35]. A steeper
decrease in the non-union group between week 2 and 4
compared to other groups could be attributed to a
decrease in hard callus formation, which plays a crucial
role in non-union formation. In our previous publica-
tions, we attributed this decrease to hard callus forma-
tion between week 2 and 4 and proposed this phase to
be crucial in nonunion formation. It is known that
TGF-β plays an important role in the formation of
cartilage-like tissue, whereas a decrease in the expres-
sion of TGF-β accounts for an impaired potential in
the formation of cartilage-like tissue. Hereby indicat-
ing that impaired expression of TGF-β, as seen in
decreased plasma levels, may provide a predisposing
factor of an dysfunctional cartilage and osseous regen-
eration [24].
In conclusion it is known that local and systemic con-
centrations of different osteogenic cytokines increase
during physiological fracture healing, in particular suffi-
cient serum concentrations of TGF-ß have been shown
to be pivotal to fracture healing [36]. It has been re-
ported that TGF-ß and BMPs are capable of inducing
each others expressions [33, 34], however patients with
failed bone healing are known to have impaired local
BMP concentration, furthermore the current study
showed that the concentration of TGF-ß in concerned
patients is decreased during the initial 12 months; indi-
cating that BMP-7 and TGF-ß have to be present in
fracture healing in a sufficient concentration [37]. Our
results show that local application of BMP-7 serves as a
substitution of impaired BMP-7 levels in non-union pa-
tients and thereby modulating the microenviroment in
the fracture gap and promoting bone regeneration. The
results of our current study accentuate the findings of
previous studies indicating that lower circulating levels
of TGF-ß could be utilized as a predictor of delayed
bone healing and non-union [11].
PDGF
Platelet derived growth factor was first discovered in
thrombocytes, but was later found in granulation tis-
sue, hypertrophic chondrocytes, osteoblasts, and oste-
oclasts during bone healing. PDGF has got many
effects on fracture healing: it releases mesenchymal
stem cells from blood vessels and is a potent mitogen
for mesenchymal stem cells (MSC) [38, 39]. It also
promotes angiogenesis by increasing the secretion of
vascular endothelial growth factor (VEGF) [12, 40].
PDGF deficiency may lead to impaired bone healing as
shown in diabetic animals [41]. After PDGF applica-
tion in osteoporotic animals, improvement was seen in
bone healing. Furthermore, PDGF application im-
proved bone healing in diabetic patients [40], more re-
cently published data indicates promising results in
the treatment of osteochondral defects of the talus,
hereby application of PDGF provides a benefit in bone
healing [42].
Our findings on PDGF concentration levels in the
union and the non-union group are supported by previ-
ous studies [12]. Union patients had higher levels at all
time points than non-union patients. Levels increased in
both groups after surgery, peaked after the fourth week,
and decreased thereafter. Similar to TGF-β, levels
decreased steeper in non-union-patients as in other
groups. We explained this by hard callus formation as
explained above. This would be supported by previous
research showing that PDGF application led to an in-
crease in callus density and volume in animal models
[43]. Patients treated with BMP-7 had higher levels of
PDGF than non-union patients; which is possibly due to
increased PDGF secretion from BMP-7 stimulation.
There was an increase in the union and the BMP-7
group between week 8 and 12, which was not detected
in non-union patients. This phase of bone healing is
associated with remodeling, which could be influenced
by PDGF. Non-unions may not have reached the remod-
eling phase, resulting in reduced cytokine levels. In con-
clusion local application of BMP-7 increases PDGF level
to a physiological extent, thereby BMP-7 substitution
enhances mitogenesis of MSCs in the initial phase of
bone healing, concluding in a possibly higher concentra-
tion of MSC in the fracture gap leading to favorable frac-
ture healing. Furthermore BMP-7 application leads to an
increased angiogenesis in the initial phase of fracture
healing by an enhanced expression of PDGF and bFGF.
The results of our study indicate that application of
BMP-7 improves bone healing by enhanced angiogen-
esis, mitogenesis and osteogenesis.
bFGF
Angiogenic growth factors are mainly expressed during
the early phases of fracture healing whereas osteogenic
growth factors are continuously expressed during bone
healing and remodeling [44]. Basic fibroblast growth fac-
tor plays an important role in the angiogenic response
after fracture healing [45], as well as in general bone
healing [46, 47]. Apparently due to complex processes:
bFGF abrogated the bone stimulating effects of BMP-7
in vitro [48, 49], and reversibly inhibited osteogenesis in
human adipose-tissue derived stromal cells [50]. BFGF
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retains MSCs in a more “immature” state and MSC lines
responding to bFGF stimulation secrete factors which
provided an environment for the first stage of fracture
repair [51]. Consequently, one putative function of bFGF
could be the retention of mesenchymal stem cells during
the first phases of fracture healing before ossification
takes place. Up to date multiple combination of osteo-
genic and angiogenic growth factors has been used and
studied in combination, however the combination of
BMPs and bFGF have been one of the most popular
growth factors used [52, 53]. Regarding the effect of the
combined application of BMP and BFGF contradictory
conclusions have been found, in particular studies have
shown stimulatory and inhibitory effects [44]. In the
present study, bFGF levels did not alter in non-unions
while significant increases in the union groups were
observed after the second week. This suggests that bFGF
plays a crucial role during the first stages of fracture
repair possibly as an angiogenic growth factor. BMP-7
application led to an enormous increase in bFGF expres-
sion and concentrations remained significantly higher
even 1 year after surgery. In particular BMP-7 applica-
tion lead to an enormous increase in the initial phase of
bone healing, indicating that BMP-7 application leads to
an enhanced angiogenesis in the early stages of bone
healing by increasing local bFGF concentrations, further-
more bFGF levels were increased during the whole
period of time, thereby promoting bone healing by a
supplementary osteogenic effect during initial bone heal-
ing and later remodeling. In conclusion the results of
our study accentuate a favorable effect of increased local
bFGF and BMP-7 concentrations on bone healing; either
due to direct stimulation of angiogenesis and osteogen-
esis due to BMP-7 application evaluated by increased
bFGF serum level or due to an initial stimulation of
bFGF expression and subsequently a co-stimulatory ef-
fect of increased local BMP-7 and bFGF concentrations.
These findings stress the significance of a molecular link
between BMP and bFGF signal pathways [54].
Limitations
Non-unions are a severe but an infrequent complica-
tion resulting in clinical studies concerning non-union
therapy being complex and it explains the small size of
our patient collective. Despite a large patient collective
just a small number of patients could be included in
the study due to our strict inclusion and exclusion cri-
teria. In the context of current literature and our
recent studies [14, 55], our patient collective size is
still sufficient. Another limitation of this study may
arise from the different age of samples, samples were
collected throughout the whole study period, however
measurements were performed cumulated for all sam-
ples, which could influence the cytokine concentration.
However, since samples of all groups were concerned
equally we believe that the sample age does not inter-
fering with the results of our study. The strengths of
this study are its prospective approach, the clear inclu-
sion and exclusion criteria, and the matching of
patients. This allowed us to eliminate factors that could
bias the evaluation of these patient groups.
Conclusions
In this prospective, controlled study, we analyzed the
serum concentrations of TGF-β, PDGF and bFGF during
a 1 year follow-up in non-union patients treated with
BMP-7. We compared them to the cytokine expression
pattern of patients with failed and with proper bone
healing to determine if the local application of BMP-7
modulates the microenvironment in the fracture gap
and thereby influences secondary bone regeneration.
The results of our study show that local application of
BMP-7 lead to a cytokine expression pattern of bone
healing associated cytokines (TGFβ, PDGF and bFGF)
that resembled the expression patterns of patients with
proper bone healing and differed significantly from those
in patients developing non-unions. Concluding in the
current study we could show that patients that develop
non-unions have an abnormal cytokine expression pat-
tern of osteogenic cytokines, in particular serum cyto-
kine levels were decreased beginning at the start of
fracture healing. Local application of BMP-7 elevated
serum cytokine level to a physiological extent and
thereby facilitated bone regeneration by enhanced angio-
genesis, mitogenesis and osteogenesis. We believe our
study adds important knowledge to the literature in the
field by providing a possible mechanism of how adjunct
application of BMP-7 promotes bone healing gathered
from clinical data.
Furthermore this present study showed that quantita-
tive measurement of serum cytokine expression is a valid
instrument in evaluating the biological impact of BMP-7
and thus the value of possible non-union therapies. Fur-
ther studies using this protocol to determine serum
cytokine expression levels will help elucidate the effect-
iveness of other non-union therapies, and compare these
therapies in order to make a biology-based decision for
the treatment of non-unions.
Ethics, consent and permission
Patients were included in our study after giving a full
written declaration of consent, including the use of the
gathered data, as well as the consent to publish the data
acquired. The study was conducted in accordance with
the declaration of Helsinki and after the approval of the
ethics committee of the Ruprechts-Karls-University of
Heidelberg (nr. 157/2002).
Moghaddam et al. Journal of Inflammation  (2016) 13:3 Page 7 of 9
Abbreviations
BMP-7: Bone morphogenic protein 7; BMP: Bone morphogenic protein;
TGF-β: Transforming growth factor beta; PDGF: Platelet-derived growth
factor; BFGF: Basic fibroblast growth factor; AO/ASIF: Association for the
study of internal fixation; SEM: Standard error of the mean;
MSC: Mesenchymal stem cell; VEGF: Vascular endothelial growth factor.
Competing interest
The authors declare that they have no competing interests.
Authors’ contribution
AM has finalized the design of the study, managed and performed the
sample acquisition and has helped in interpretation of the data as well as
revising the manuscript. LB has performed the serum cytokine expression
analysis and helped to draft the manuscript. PH has helped in interpretation
of the data as well as helped to draft the manuscript and revised it
critically for important intellectual content. DB participated in the design
of the study and helped in performing the statistical analysis. BB has
helped in interpretation of the data and revised the manuscript. AW
participated in the design of the study. GZ participated in the design
and coordination of the study, helped in the interpretation of data and
helped to draft and revise the manuscript. All authors read and
approved the final manuscript.
Authors’ information
AM: consultant for orthopaedic surgery and trauma surgery at the University
Hospital Heidelberg. LB: resident for orthopaedic surgery and trauma surgery
at the St. Marienkrankenhaus. PH: resident for orthopaedic surgery and
trauma surgery at the University Hospital Heidelberg. DB: resident for
anesthesiology at the Hospital Frankenthal. BB: head of the Department for
paraplegiology and technical orthopaedics at the BG Trauma Center. AW:
former director of BG Trauma Center. GZ: head of the department for trauma
surgery at the Theresienkrankenhaus and St. Hedwigs-Klinik GmbH.
Acknowledgements
We acknowledge the financial support of the Deutsche Forschungsgemeinschaft
and Ruprecht-Karls-Universität Heidelberg within the funding program Open
Access Publishing.
Author details
1HTRG - Heidelberg Trauma Research Group, Trauma and Reconstructive
Surgery, Center of Orthopaedics, Traumatology and Paraplegiology,
Heidelberg University Hospital, Schlierbacher Landstraße 200a, D-69118
Heidelberg, Germany. 2Department of Orthopaedics and Traumatology, St.
Marienkrankenhaus, Salzburger Str. 15, 67067 Ludwigshafen, Germany.
3Department for anesthesiology, Stadtklinik Frankenthal, Elsa-Brändenström
Str. 1, D-67227 Frankenthal, Germany. 4Berufsgenossenschaftliche Unfallklinik
Ludwigshafen, Department of Paraplegiology, Ludwig-Guttmann-Straße-13,
D-67071 Ludwigshafen, Germany. 5Berufsgenossenschaftliche Unfallklinik
Ludwigshafen, Trauma Center, Ludwig-Guttmann-Straße-13, D-67071
Ludwigshafen, Germany. 6Department for Trauma Surgery,
Theresienkrankenhaus und St. Hedwigs-Klinik GmbH, Bassermannstr. 1,
D-68165 Mannheim, Germany.
Received: 19 June 2015 Accepted: 19 January 2016
References
1. Schmidmaier G, Moghaddam A. Long bone nonunion. Z Orthop Unfall.
2015;153(6):659–76. doi:10.1055/s-0035-1558259.
2. Rodriguez-Merchan EC, Forriol F. Nonunion: general principles and
experimental data. Clin Orthop Relat Res. 2004;419:4–12.
3. Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques.
J Bone Joint Surg Am. 2011;93(23):2227–36. doi:10.2106/JBJS.J.01513.
4. Janicki P, Schmidmaier G. What should be the characteristics of the ideal
bone graft substitute? Combining scaffolds with growth factors and/or
stem cells. Injury. 2011;42 Suppl 2:S77–81. doi:10.1016/j.injury.2011.06.014.
5. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: an update. Injury.
2005;36 Suppl 3:S20–7. doi:10.1016/j.injury.2005.07.029.
6. Shah P, Keppler L, Rutkowski J. Bone morphogenic protein: an elixir for
bone grafting–a review. Eur J Oral Implantol. 2012;38(6):767–78. doi:10.1563/
AAID-JOI-D-10-00196.
7. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, et al. Bone
morphogenetic protein (BMP) for fracture healing in adults. Cochrane
Database Syst Rev. 2010;6:CD006950. doi:10.1002/14651858.CD006950.pub2.
8. TRACP. 5b and CTX as osteological markers of delayed fracture healing. 2010.
9. Bishop JA, Palanca AA, Bellino MJ, Lowenberg DW. Assessment of
compromised fracture healing. J Am Acad Orthop Surg. 2012;20(5):273–82.
doi:10.5435/JAAOS-20-05-273.
10. den Boer FC, Wippermann BW, Blokhuis TJ, Patka P, Bakker FC, Haarman HJ.
Healing of segmental bone defects with granular porous hydroxyapatite
augmented with recombinant human osteogenic protein-1 or autologous
bone marrow. J Orthop Res. 2003;21(3):521–8. doi:10.1016/S0736-
0266(02)00205-X.
11. Zimmermann G, Henle P, Kusswetter M, Moghaddam A, Wentzensen A,
Richter W, et al. TGF-beta1 as a marker of delayed fracture healing. Bone.
2005;36(5):779–85. doi:10.1016/j.bone.2005.02.011.
12. Weiss S, Henle P, Bidlingmaier M, Moghaddam A, Kasten P, Zimmermann G.
Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing.
Growth Horm IGF Res. 2008;18(3):205–12. doi:10.1016/j.ghir.2007.09.002.
13. Weiss S, Zimmermann G, Pufe T, Varoga D, Henle P. The systemic
angiogenic response during bone healing. Arch Orthop Trauma Surg. 2009;
129(7):989–97. doi:10.1007/s00402-008-0777-5.
14. Moghaddam A, Muller U, Roth HJ, Wentzensen A, Grutzner PA,
Zimmermann G. TRACP 5b and CTX as osteological markers of delayed
fracture healing. Injury. 2011;42(8):758–64. doi:10.1016/j.injury.2010.11.017.
15. Moghaddam A, Weiss S, Wolfl CG, Schmeckenbecher K, Wentzensen A, Grutzner
PA, et al. Cigarette smoking decreases TGF-b1 serum concentrations after long
bone fracture. Injury. 2010;41(10):1020–5. doi:10.1016/j.injury.2010.03.014.
16. Moghaddam A1, Weiss S, Wölfl CG, Schmeckenbecher K, Wentzensen A,
Grützner PA, et al. Cigarette smoking decreases TGF-β1 serum
concentrations after long bone fracture, (2010).
17. Bosemark P, Perdikouri C, Pelkonen M, Isaksson H, Tagil M. The
masquelet induced membrane technique with BMP and a synthetic
scaffold can heal a rat femoral critical size defect. J Orthop Res. 2015;
33(4):488–95. doi:10.1002/jor.22815.
18. Moghaddam-Alvandi A, Zimmermann G, Buchler A, Elleser C, Biglari B,
Grutzner PA, et al. Results of nonunion treatment with bone
morphogenetic protein 7 (BMP-7). Unfallchirurg. 2012;115(6):518–26. doi:10.
1007/s00113-011-2100-0.
19. Karger C, Kishi T, Schneider L, Fitoussi F, Masquelet AC. Treatment of
posttraumatic bone defects by the induced membrane technique. Orthop
Traumatol Surg Res. 2012;98(1):97–102. doi:10.1016/j.otsr.2011.11.001.
20. Pelissier P, Masquelet AC, Bareille R, Pelissier SM, Amedee J. Induced
membranes secrete growth factors including vascular and osteoinductive
factors and could stimulate bone regeneration. J Orthop Res. 2004;22(1):73–
9. doi:10.1016/s0736-0266(03)00165-7.
21. Masquelet AC, Begue T. The concept of induced membrane for
reconstruction of long bone defects. The Orthopedic clinics of North
America. 2010;41(1):27–37; table of contents. doi:10.1016/j.ocl.2009.07.011.
22. Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts,
osteomies, and implants fixation. Acta Orthop Scand Suppl. 1998;283:2–37.
23. Patil AS, Sable RB, Kothari RM. An update on transforming growth
factor-beta (TGF-beta): sources, types, functions and clinical applicability
for cartilage/bone healing. J Cell Physiol. 2011;226(12):3094–103. doi:10.
1002/jcp.22698.
24. Tekari A, Luginbuehl R, Hofstetter W, Egli RJ. Transforming growth factor
Beta signaling is essential for the autonomous formation of cartilage-like
tissue by expanded chondrocytes. PLoS One. 2015;10(3):e0120857. doi:10.
1371/journal.pone.0120857.
25. Wang CJ, Yang KD, Ko JY, Huang CC, Huang HY, Wang FS. The effects of
shockwave on bone healing and systemic concentrations of nitric oxide
(NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions. Nitric oxide.
2009;20(4):298–303. doi:10.1016/j.niox.2009.02.006.
26. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in
clinical applications. ANZ J Surg. 2007;77(8):626–31. doi:10.1111/j.1445-
2197.2007.04175.x.
27. Takemoto R, Forman J, Taormina DP, Egol KA. No advantage to rhBMP-2 in
addition to autogenous graft for fracture nonunion. Orthopedics. 2014;37(6):
e525–30. doi:10.3928/01477447-20140528-51.
Moghaddam et al. Journal of Inflammation  (2016) 13:3 Page 8 of 9
28. Borrelli Jr J, Prickett WD, Ricci WM. Treatment of nonunions and osseous
defects with bone graft and calcium sulfate. Clin Orthop Relat Res. 2003;411:
245–54. doi:10.1097/01.blo.0000069893.31220.6f.
29. Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of
members of the transforming growth factor beta superfamily during
murine fracture healing. J Bone Miner Res. 2002;17(3):513–20. doi:10.
1359/jbmr.2002.17.3.513.
30. Giannoudis PV, Kanakaris NK, Dimitriou R, Gill I, Kolimarala V, Montgomery
RJ. The synergistic effect of autograft and BMP-7 in the treatment of
atrophic nonunions. Clin Orthop Relat Res. 2009;467(12):3239–48. doi:10.
1007/s11999-009-0846-2.
31. Moghaddam A, Zietzschmann S, Bruckner T, Schmidmaier G. Treatment of
atrophic tibia non-unions according to ‘diamond concept’: Results of one-
and two-step treatment. Injury. 2015;46 Suppl 4:S39–50. doi:10.1016/S0020-
1383(15)30017-6.
32. Niikura T, Hak DJ, Reddi AH. Global gene profiling reveals a downregulation of
BMP gene expression in experimental atrophic nonunions compared to standard
healing fractures. J Orthop Res. 2006;24(7):1463–71. doi:10.1002/jor.20182.
33. Tim CR, Bossini PS, Kido HW, Malavazi I, von Zeska Kress MR, Carazzolle MF,
et al. Effects of low-level laser therapy on the expression of osteogenic
genes during the initial stages of bone healing in rats: a microarray analysis.
Lasers Med Sci. 2015;30(9):2325–33. doi:10.1007/s10103-015-1807-5.
34. Buttner M, Moller S, Keller M, Huster D, Schiller J, Schnabelrauch M, et al.
Over-sulfated chondroitin sulfate derivatives induce osteogenic
differentiation of hMSC independent of BMP-2 and TGF-beta1 signalling. J
Cell Physiol. 2013;228(2):330–40. doi:10.1002/jcp.24135.
35. Gerstenfeld LC1, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture
healing as a post-natal developmental process: Molecular, spatial, and
temporal aspects of its regulation, (2003).
36. Binder H, Eipeldauer S, Gregori M, Hochtl-Lee L, Thomas A, Tiefenboeck TM,
et al. The difference between growth factor expression after single and
multiple fractures: preliminary results in human fracture healing. Dis Markers.
2015;2015:203136. doi:10.1155/2015/203136.
37. Glueck M, Gardner O, Czekanska E, Alini M, Stoddart MJ, Salzmann GM, et al.
Induction of osteogenic differentiation in human mesenchymal stem cells
by crosstalk with osteoblasts. BioRes Open Access. 2015;4(1):121–30. doi:10.
1089/biores.2015.0002.
38. Caplan AI, Correa D. PDGF in bone formation and regeneration: new
insights into a novel mechanism involving MSCs. J Orthop Res. 2011;29(12):
1795–803. doi:10.1002/jor.21462.
39. Tan HB, Giannoudis PV, Boxall SA, McGonagle D, Jones E. The systemic
influence of platelet-derived growth factors on bone marrow
mesenchymal stem cells in fracture patients. BMC med. 2015;13:6.
doi:10.1186/s12916-014-0202-6.
40. Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant
human platelet-derived growth factor: biology and clinical applications.
J Bone Joint Surg Am. 2008;90 Suppl 1:48–54. doi:10.2106/JBJS.G.01231.
41. Tyndall WA, Beam HA, Zarro C, O’Connor JP, Lin SS. Decreased platelet
derived growth factor expression during fracture healing in diabetic
animals. Clin Orthop Relat Res. 2003;408:319–30.
42. Younger A, Wing K, Penner M, Cresswell M. A study to evaluate the safety
of platelet-derived growth factor for treatment of osteochondral defects of
the talus. Knee surgery, sports traumatology, arthroscopy : official journal of
the ESSKA. 2015. doi:10.1007/s00167-015-3549-0.
43. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ. Effect of
platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994;
15(2):203–8.
44. Chen T, Gomez AW, Zuo Y, Li X, Zhang Z, Li Y et al. Osteogenic potential
and synergistic effects of growth factors delivered from a bionic composite
system. Journal of biomedical materials research Part A. 2015. doi:10.1002/
jbm.a.35605
45. Saadeh PB, Mehrara BJ, Steinbrech DS, Spector JA, Greenwald JA, Chin GS,
et al. Mechanisms of fibroblast growth factor-2 modulation of vascular
endothelial growth factor expression by osteoblastic cells. Endocrinology.
2000;141(6):2075–83. doi:10.1210/endo.141.6.7502.
46. Hanada K, Dennis JE, Caplan AI. Stimulatory effects of basic fibroblast
growth factor and bone morphogenetic protein-2 on osteogenic
differentiation of rat bone marrow-derived mesenchymal stem cells.
J Bone Miner Res. 1997;12(10):1606–14. doi:10.1359/jbmr.1997.12.10.1606.
47. Kawaguchi H, Nakamura K, Tabata Y, Ikada Y, Aoyama I, Anzai J, et al. Acceleration
of fracture healing in nonhuman primates by fibroblast growth factor-2. J Clin
Endocrinol Metab. 2001;86(2):875–80. doi:10.1210/jcem.86.2.7199.
48. Chaudhary LR, Hofmeister AM, Hruska KA. Differential growth factor control
of bone formation through osteoprogenitor differentiation. Bone. 2004;
34(3):402–11. doi:10.1016/j.bone.2003.11.014.
49. Nelson ER, Huang Z, Ma T, Lindsey D, Jacobs C, Smith RL, et al. New bone
formation by murine osteoprogenitor cells cultured on corticocancellous
allograft bone. J Orthop Res. 2008;26(12):1660–4. doi:10.1002/jor.20676.
50. Quarto N, Longaker MT. FGF-2 inhibits osteogenesis in mouse adipose
tissue-derived stromal cells and sustains their proliferative and osteogenic
potential state. Tissue Eng. 2006;12(6):1405–18. doi:10.1089/ten.2006.12.1405.
51. Tasso R, Gaetani M, Molino E, Cattaneo A, Monticone M, Bachi A, et al. The
role of bFGF on the ability of MSC to activate endogenous regenerative
mechanisms in an ectopic bone formation model. Biomaterials. 2012;33(7):
2086–96. doi:10.1016/j.biomaterials.2011.11.043.
52. Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth
factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012;64(12):
1292–309. doi:10.1016/j.addr.2012.01.016.
53. Chen FM, Zhang M, Wu ZF. Toward delivery of multiple growth factors in
tissue engineering. Biomaterials. 2010;31(24):6279–308. doi:10.1016/j.
biomaterials.2010.04.053.
54. Rice R, Rice DP, Thesleff I. Foxc1 integrates Fgf and Bmp signalling
independently of twist or noggin during calvarial bone development. Dev
Dyn. 2005;233(3):847–52. doi:10.1002/dvdy.20430.
55. Westhauser F, Zimmermann G, Moghaddam S, Bruckner T, Schmidmaier G,
Biglari B, et al. Reaming in treatment of non-unions in long bones: cytokine
expression course as a tool for evaluation of non-union therapy. Arch
Orthop Trauma Surg. 2015;135(8):1107–16. doi:10.1007/s00402-015-2253-3.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Moghaddam et al. Journal of Inflammation  (2016) 13:3 Page 9 of 9
